When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

Jared R. Adams; Cara Angelotta; Charles L. Bennett

doi:10.1200/JCO.2006.05.6812

When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

Jared R. Adams^*, Cara Angelotta, Charles L. Bennett

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Editorial › peer-review

18 Scopus citations

Original language	English (US)
Pages (from-to)	2975-2977
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	24
Issue number	19
DOIs	https://doi.org/10.1200/JCO.2006.05.6812
State	Published - Jul 1 2006

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2006.05.6812

Cite this

@article{02a24f7cdbaf436c99395b1a3cab15a3,

title = "When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?",

author = "Adams, {Jared R.} and Cara Angelotta and Bennett, {Charles L.}",

year = "2006",

month = jul,

day = "1",

doi = "10.1200/JCO.2006.05.6812",

language = "English (US)",

volume = "24",

pages = "2975--2977",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",